![]() |
市场调查报告书
商品编码
1374432
全球玻璃化市场规模、份额、产业趋势分析报告:2023-2030 年按检体、最终用途和地区分類的展望和预测Global Vitrification Market Size, Share & Industry Trends Analysis Report By Specimen (Oocytes (Devices, Kits & Consumables), Embryo (Devices, Kits & Consumables), and Sperm), By End-use, By Regional Outlook and Forecast, 2023 - 2030 |
预计到 2030 年,玻璃化市场规模将达到 241 亿美元,预测期内年复合成长率为 17.2%。
然而,有些人不喜欢人工创造生命的想法,如果听之任之,生命就不会存在。还有一种观点认为我们应该把它留给「自然选择」。一夫一妻制婚姻制度和人类生命的尊严都受到体外受精的影响。受精儿童也会出现身分问题。即使在人类生命的最初阶段,从受孕开始,它就具有巨大的意义。可能影响社会和医疗保健专业人员的法律问题包括医疗事故指控、未成年患者的知情同意以及法定监护权。这些有关体外受精和生育力保存的伦理和技术问题可能会阻碍市场扩张。
此外,COVID-19 大流行对全球经济产生了重大影响,医疗保健产业也未能倖免。疫情对市场产生了负面影响。国际生育协会建议,在世界卫生组织 (WHO) COVID-19 大流行期间,除必要的医学生育力保存外,不要继续进行 IVF 治疗。然而,随着 COVID-19 限制的放鬆,IVF 诊所和其他医疗机构可以在采取预防措施的情况下重新开放,例如配备足够的工作人员并遵循适当的安全协议。这些因素都有助于市场在疫情后的早期復苏。
展望检体
依检体,市场分为卵子、胚胎和精子。 2022 年,胚胎细分市场在市场中获得了可观的收益占有率。额外的胚胎被玻璃化保存。体外受精从业者将较少的新鲜胚胎传输到子宫中,以减少多胎妊娠的机会。如果第一个週期失败,可以进行冷冻胚胎移植,而不是再次经历卵巢刺激和取卵的不便。
卵子前景
卵子部分进一步细分为设备和套件及消耗品。 2022 年,套件和消耗品部门在市场上获得了可观的收益占有率。卵子玻璃化冷冻在生育力保存和辅助生殖技术中的成功取决于所用材料和程序的品质。玻璃化套件和消耗品可确保卵子保存时具有高活力和发育潜力,从而对该技术的整体成功率做出重大贡献。
胚胎视角
胚胎部分进一步分为设备、套件和消耗品。在 2022 年的市场中,设备细分市场占据了最大的收益占有率。玻璃化装置,如吸管、小瓶或特殊容器,可作为胚胎的保护罩。它们在玻璃化过程中安全地容纳胚胎,同时防止直接暴露于冷冻保护剂溶液并最大限度地减少物理损坏的风险。该装置设计用于容纳特定体积的玻璃化溶液和胚胎。
最终用途展望
根据最终用途,市场分为 IVF 诊所和生物库。 2022年,IVF诊所部门占据市场最大的收益占有率。越来越多的 IVF 诊所提供玻璃化冷冻和其他 ART 服务,这可能会带来可观的收益占有率。此外,该诊所还提供精子、卵子和卵子储存等服务,预计将增加诊所的收入份额。玻璃化冷冻技术在体外受精的进展率以及冷冻卵子和胚胎的週期数方面显着改善了生殖医疗环境。
区域展望
按地区划分,对北美、欧洲、亚太地区和拉丁美洲地区市场进行了分析。 2022 年,欧洲地区占据最大的收益占有率,引领市场。法国、西班牙、英国、英国和义大利等新兴经济体对此负有责任。由于这些国家基础设施发达,预计该地区的低温保存技术将大幅增加。此外,在英国和德国等国家,生物技术部门的扩张以及对辅助生殖技术市场开拓的财政支持正在促进市场成长。不孕症的高发生率和女性对卵子保存的兴趣日益浓厚是该地区发展的主要驱动力。
The Global Vitrification Market size is expected to reach $24.1 billion by 2030, rising at a market growth of 17.2% CAGR during the forecast period.
Male fertility preservation and sperm cryopreservation are both crucial components of ART. It can help individuals with azoospermia or oligozoospermia avoid recurrent biopsies. Thus, the sperm segment will capture 1/5th share in the revenue by the year 2030. Before having chemotherapy or radiation therapy, cancer patients can also use this procedure to maintain their fertility. The standard freezing approach can achieve an adequate survival rate since mature sperm have a significant number and little volume and also tolerate freezing temperatures well. Some of the factors impacting the market are growing demand for organ transplants, rising percentage of first-time mothers at an older median age and ethical, and technical issues with IVF and fertility preservation.
Various reasons, such as pointless injury, poisoning, blood loss, drug abuse, etc., can cause organ failure. The rising incidence of renal disease, excessive alcohol use, and poor diet have pushed the growth of organ transplantation. Growing global organ donation also influences people's attitudes toward organ transplantation. By transforming them into a glass-like condition, vitrification enables the conservation of organs at extremely low temperatures (-196°C or -320°F). This makes it possible to store organs for a long time-possibly from hours to days-without any actual degradation. Additionally, over time, there has been a sharp increase in the median age of first-time mothers globally. More effective contraceptive methods, later marriages, and an increase in women prioritizing their careers over having children are the leading causes of this trend. Because of this, it is projected that as the average age of first-time mothers increases, more women will experience trouble conceiving naturally. More women are being forced to seek IVF treatments in this situation. The market is, therefore, anticipated to grow along with the rise in demand for organ transplants.
However, some individuals dislike the idea of artificially created life that couldn't exist if nature were left to itself. Another argument they can raise is that "natural selection" should be allowed to carry out its task. The institution of monogamous marriage and the sanctity of human life are both affected by in vitro fertilization. For the children who are conceived, it also raises issues with identity. Even in its earliest phases, starting with conception, human life has immense significance. Legal issues that could affect society and healthcare professionals include allegations of medical malpractice, informed consent from patients who are minors, and legal parentage. These ethical and technical issues with IVF and fertility preservation may hinder the market's expansion.
Additionally, the COVID-19 pandemic had a significant effect on the global economy; the healthcare industry was not exempted from this. The pandemic had a negative impact on the market. International fertility associations advised against continuing IVF therapy during the World Health Organization's (WHO) COVID-19 pandemic, except for necessary medical fertility preservation. However, the relaxation of COVID-19 limitations allowed IVF clinics and other healthcare facilities to reopen with precautions like ensuring adequate staff and adhering to appropriate safety procedures. In light of these elements, these factors aided in the market's quick recovery in the post-pandemic era.
Specimen Outlook
On the basis of specimen, the market is segmented into oocytes, embryos, and sperm. In 2022, the embryo segment acquired a substantial revenue share in the market. Extra embryos are vitrified to preserve them. IVF practitioners transfer fewer fresh embryos into the uterus to reduce the chance of multiple pregnancies. A frozen embryo transfer may be performed if the first cycle is unsuccessful rather than going through the inconveniences of ovarian stimulation and egg retrieval again.
Oocytes Outlook
The oocytes segment is further subdivided into devices and kits & consumables. The kits and consumables segment procured a significant revenue share in the market in 2022. The success of oocyte vitrification in fertility preservation and ART depends on the quality of the materials and procedures used. Vitrification kits and consumables contribute significantly to the overall success rate of the technique, ensuring that oocytes are preserved with high viability and developmental potential.
Embryo Outlook
The embryo segment is further bifurcated into devices and kits & consumables. The devices segment acquired the largest revenue share in the market in 2022. Vitrification devices, such as straws, vials, or specialized containers, serve as protective enclosures for embryos. They keep embryos securely contained during the vitrification process, preventing direct exposure to cryoprotectant solutions and minimizing the risk of physical damage. Devices are engineered to hold specific volumes of vitrification solutions and embryos.
End Use Outlook
Based on end-use, the market is fragmented into IVF clinics and biobanks. In 2022, the IVF clinics segment witnessed the largest revenue share in the market. The significant revenue share may result from the growing number of IVF clinics that provide vitrification and other ART services. Furthermore, the clinics are providing services like sperm, egg, and oocyte storage, which is anticipated to increase the income share of clinics. Regarding the IVF progress rate and the number of freezing cycles for oocytes and embryos, the vitrification technique considerably enhances the reproductive health environment.
Regional Outlook
Region-wise, the market is analyzed across North America, Europe, Asia Pacific, and LAMEA. In 2022, the Europe region led the market by generating the largest revenue share. The existence of developed economies like those of France, Spain, Germany, the UK, and Italy is responsible for this. Because of the developed infrastructure in these nations, cryopreservation techniques are expected to increase dramatically in the region. Furthermore, the biotechnology sector's expansion and financial support for the development of assisted reproductive technologies in nations like the UK and Germany contribute to market growth. The high incidence of infertility and rising interest among women in egg preservation are the main drivers of regional development.
The market research report covers the analysis of key stakeholders of the market. Key companies profiled in the report include Vitrolife AB, Genea Limited (Liverpool Partners Group), NidaCon International AB, Minitub GmbH, Cryo Bio System (IMV Technologies Group), CooperSurgical Fertility & Genomic Solutions (The Cooper Companies, Inc.), FUJIFILM Irvine Scientific, Inc. (Fujifilm Holdings Corporation), Biotech, Inc., Kitazato Corporation and Shenzhen VitaVitro Biotech
Market Segments covered in the Report:
By Specimen
By End-use
By Geography
Companies Profiled
Unique Offerings from KBV Research